Investing.com - Financial Markets Worldwide
👀 Copy Legendary Investors' Portfolios in One ClickCopy For Free

European shares dip; UK vaccine approval limits losses on FTSE 100

Published 12/02/2020, 04:14 PM
Updated 12/02/2020, 04:20 PM
© Reuters.
UK100
-
DE40
-
STOXX
-
SXEP
-
BNTX
-

(For a live blog on European stocks, type LIVE/ in an Eikon
news window)
Dec 2 (Reuters) - European shares slipped on Wednesday as
investors took stock following a near 14% rally last month,
while shares in BioNTech surged after UK became the first
country to approve its COVID-19 vaccine developed with Pfizer.
London's blue-chip index .FTSE outperformed regional
peers, losing just 0.1% after Britain said the vaccine will be
rolled out from next week. BioNtech's Frankfurt-listed shares 22UAy.F jumped 8.4%,
while Germany's benchmark DAX index .GDAXI fell 0.5% despite
data showing a higher-than-expected rebound in retail sales in
Europe's largest economy in October. The pan-European STOXX 600 index .STOXX was down 0.4% with
oil stocks .SXEP leading declines, as crude prices were hit by
a surprise build up in oil inventories in the U.S. and as OPEC
and its allies left markets in limbo about production in
January. O/R

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.